---
schema_version: "secwatch.filing_event.v1"
accession: "0001830214-25-000013"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:57:59.981753+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Q3 revenue $39M (-56% YoY); net loss $81M; reaffirms FY guide $167-187M

## Summary
- Total revenue $39M, down 56% YoY; prior year had $45M non-cash deferred revenue; ex that, down 11%.
- GAAP net loss $81M vs $56M prior; Adjusted EBITDA loss $56M vs $20M.
- Reaffirms FY25 revenue $167-187M; Cell Engineering $117-137M; Biosecurity at least $40M.
- Cash & securities $462M; expands autonomous lab; Bayer partnership extended, BARDA contract up to $22.2M.
- Cell Engineering revenue $29M (-61% YoY); Biosecurity $9M ($14M prior).

## SEC filing metadata
- accession: 0001830214-25-000013
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000183021425000013/0001830214-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000183021425000013/dna-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001830214-25-000013
- JSON: https://secwatch.observer/filing/0001830214-25-000013.json
- Plain text: https://secwatch.observer/filing/0001830214-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.